Finanzen von Bio Green Med Solution Inc (BGMS)BGMSBio Green Med Solution Inc

Evaluating the bottom line, Bio Green Med Solution Inc maintains a gross margin of 23.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -124.40%, while the net margin is -120.54%. These profitability ratios, combined with a Return on Equity (ROE) of -171.64%, provide a clear picture of how effectively BGMS converts its operational activities into shareholder value.

In the context of the broader market, BGMS competes directly with industry leaders such as CNSP and ACXP. With a market capitalization of $5.69M, it holds a significant position in the sector. When comparing efficiency, BGMS's gross margin of 23.51% stands against CNSP's N/A and ACXP's N/A. Such benchmarking helps identify whether Bio Green Med Solution Inc is trading at a premium or discount relative to its financial performance.

Bio Green Med Solution has shown volatility in its financial performance, with total revenue of $666,000 in Q4 2025 and a net income loss of -611,000 in the same quarter. The gross margin has fluctuated, reaching 23.51% in Q2 2026, but the overall trend indicates financial instability.